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Power calculations  
 
Power estimation was performed in R 
(https://genome.sph.umich.edu/wiki/Power_Calculations:_Quantitative_Traits) and the additive 
variance formula came from Falconer D.S.1. With our Pan-Ancestry meta-analysis of up to 1,318,884 
individuals, we have 80% power to detect association with a variant with H2 of 0.003%, which 
corresponds to a variant with MAF of 0.01 and effect size of 0.039, or a variant with MAF=0.05 and 
effect size of 0.018 (Supplementary Figure 2). The effect sizes in our analyses are in terms of standard 
deviation (SD) units. 
 
Study-level analyses 
Each contributing Stage 1 study conducted exome-wide analyses of inverse normal transformed SBP, 
DBP and PP as well as HTN. The analyses of the transformed traits were performed to minimize 
sensitivity to deviations from normality in the analysis and discovery of rare variants. The residuals 
from the null model obtained after regressing the medication-adjusted trait on the covariates (age, age2, 
sex, BMI, principal components [PCs] to adjust for population stratification, in addition to any study-
specific covariates) within a linear regression model, were ranked and inverse normalized. These 
normalized residuals were used to test trait-SNV associations using RMW2 version 4.13.3 by all 
studies except four studies which used SNPTEST v2.5.1 (EPIC-Norfolk, Fenland-GWAS, Fenland-
OMICS and EPIC-InterAct-GWAS: Supplementary Table 23), assuming an additive allelic effects 
model and two-sided tests with a linear or linear mixed regression model. All SNVs that passed quality 
control were analysed for association with the continuous traits without any further filtering by MAF. 
For HTN, only SNVs with a minimum minor allele count (MAC) of 10 were analysed.  
Quality control of study level data was performed centrally and included plots comparing the inverse 
of the standard error versus square root of sample size for each study to detect any issues with trait 
transformations, and checks for concordant MAFs across studies. Five studies (CARDIA, NFBC1986, 
ALSPAC_Mothers, WHI: African Americans and WHI: Europeans) were excluded from analyses of 
HTN as they have insufficient numbers of hypertensive cases to provide reliable estimates. We did not 
observe excessively high inflation in study level data (maximum lambda=1.06, 1.07, 1.14 for SBP, 





EAWAS Study design 
 
We curated a list of 362 BP-associated loci that were known at the time of the analyses and 
conservatively defined known loci using both distance (±500kb) and LD such that variants outside of 
the known loci had r2 < 0.1 (in 1000 Genomes EUR) with the previously reported variants (Methods; 
Supplementary Table 1). Single variant association summaries for 382 SNVs with P<5x10-8 (derived 
from two-sided tests) outside of these regions (Stage 1) was requested from MVP, deCODE and 
GENOA. Results obtained from MVP, deCODE and GENOA was meta-analysed. Meta-analyses of 
Stage 1 and the results from meta-analyses of MVP, deCODE and GENOA was performed and any 
variant with P-value<5x10-8 and consistent direction of effects with no evidence for heterogeneity 
were considered new. 
Three hundred and forty-four SNVs (200 genomic regions; eight rare SNVs, 25 low-frequency SNVs; 
Methods) of the 382 BP-associated SNVs (91%) were associated with one or more BP traits at P<5x10-
8 in the combined EUR (Stage 2) meta-analyses involving up to ~1.165 million individuals (Table 1, 
Supplementary Table 2, Figure 2). An additional seven SNVs from seven genomic regions were only 
genome-wide significant in the PA (Stage 2) meta-analyses of ~1.3 million individuals (Supplementary 
Table 2), bringing the total number of BP-associated SNVs in Stage 2 to 355. Of the novel EUR BP-
associated SNVs, 41 (30 loci; three rare SNVs, four low-frequency SNVs) were associated with an 
additional BP trait in the PA meta-analyses in addition to the EUR associated trait. All the associations 
had consistent directions of effect across Stage 1 and also across Stage 2 and no evidence of 
heterogeneity (P>0.0001; Supplementary Table 2).  
 
Quality Control of novel BP-associated variants from EAWAS and RV-GWAS 
 
We adopted a single discovery-stage meta-analysis study design for both the EAWAS and RV-GWAS 
primarily for reasons of statistical power. The data request studies were not statistically powered on 
their own to detect the effects of the subset of SNVs we selected for data request from 
MVP/deCODE/GENOA (EAWAS) or MVP (RV-GWAS) since these studies involved only around 
half the samples of the discovery. For a replication study, a sample size similar to, or larger than that 
used for the discovery, is required to have sufficient statistical power. In the absence of a well powered 
replication dataset, we have taken exhaustive measures to ensure the robustness of our findings.  
 
We ensured that novel BP-associated variants that we claim were not driven by a single study. All 
reported variants had data from  19 studies in the Stage 1 EAWAS and 2 studies in the RV-GWAS, 
reducing the likelihood of a false association. In addition, all the novel BP-associated variants we 
report had consistent directions of effect in the Stage 1 studies and the data request studies 
(MVP+deCODE+GENOA for EAWAS, MVP alone for RV-GWAS). We verify the assumption of the 
fixed effects meta-analysis model, we ensured there was no evidence of heterogeneity across the effect 
estimates from contributing studies. In addition, we performed random effects meta-analysis (Han and 
Eskin’s AJHG 2011 Random Effects Model) of novel BP-associated variants to minimise false 
discoveries due to study heterogeneity. The below plot (Supplementary Figure 3a) compares the -
log10(P-values) from the fixed effect and random effects meta-analyses for all the variants in the 
EAWAS for which data were requested in the look up studies (see Supplementary Table 2a). There is 
strong concordance, suggesting that a fixed effects meta-analysis model is appropriate. 
 
To ensure that the frequency of variants are not a result of inaccurate clustering/genotype calling, we 
confirmed that the allele frequencies were in the expected range by comparing the allele frequencies 
between Stage 1 and the data request studies (MVP+deCODE+GENOA for the EAWAS and MVP 
alone for RV-GWAS, Supplementary Figure 3b). In addition, we compared the allele frequencies to 
those in the reference datasets (gnomAD, UCSC, and 1000 Genomes). Allele frequencies were plotted 
to check for consistency and those not consistent were removed e.g. rs7775698. The plot below shows 
the comparison of MAFs of novel variants in EAWAS between Stage 1 and MVP+deCODE+GENOA. 
 
Where variants were only available in a small number of studies, we checked the cluster plots of the 
studies involved and such variants as rs201702041, rs200510006, rs142360750 and rs143226982 that 
were poorly clustered in the PROMIS study were removed. 
 
Within UK Biobank we performed our own QC for the genotyped variants rather than using the QC’d 
data as provided by UK Biobank, as we were specifically interested in the rare variants and knew that 
these were most vulnerable to clustering errors. Also described in detail within the section: “UK 
Biobank specific analyses” in this document. For the RV-GWAS and the FINEMAP analyses of UK 
Biobank we were able to perform additional checks for some of the variants. We compared the minor 
allele frequencies of the variants genotyped by arrays or imputed with those genotyped using whole 
exome sequencing. For the three novel BP-associated variants we identified in UK Biobank (rather 
than the EAWAS), the MAF was consistent between the imputed and WES data, suggesting the 
genotyping was robust. 
 
Variants 1: Chromosome: 1; Position: 198,222,215 
 rsID: rs55833332 
 MAF in WES (both versions of calling/QC): 0.00747 
 MAF for the imputed variant in UKBB: 0.00816 
 MAF of variant in gnomAD v2.1.1 (for reference): 0.006475 (exomes), 0.008991 
(genomes) and 0.009749 (European non-Finnish) 
 
Variant 2:  Chromosome: 20; Position: 61,050,522 
 rsID: rs200383755 
 MAF in WES (both versions of calling/QC): 0.00680 
 MAF for the imputed variant in UKBB: 0.00601 
 MAF of variant in gnomAD v2.1.1 (for reference): 0.003412 (exomes), 0.003479 
(genomes) and 0.005443 (European non-Finnish) 
 
Variant 3 (was imputed): Chromosome: 14; Position: 100,143,685 
 rsID: rs149250178 
MAF in WES (both versions of calling/QC): 0.00020 
 MAF for the imputed variant in UKBB: 0.00036 
 MAF of variant in gnomAD v2.1.1 (for reference): no variant (exomes), 0.003479 
(genomes) and 0.001104 (European non-Finnish) 
 
We compared the minor allele frequency (MAF) calculated using genotyped genotypes and imputed 
genotypes of the rare variants both genotyped and imputed in UKBB. We looked at this distribution 
as a function of the INFO score and identified that the MAF of the imputed variants with INFO>0.3 
had an almost perfect correlation (ρ>0.9998) with the MAF of genotyped variants. Based on this 
comparison we only analysed rare variants with an INFO>0.3 in UKBB. We checked imputation 
quality for any BP-associated variant that was claimed and imputed. All variants we claim had 
imputation info score >0.8 in all Stage 1 studies. 
 
Associations of previously reported variants in the Stage 1 EAWAS and UKBB 
 
Of the 362 BP-associated loci reported prior to our analyses (i.e. pre-2018; Methods; Supplementary 
Table 1), 291 (80%) had one or more genome-wide significant associations in our UKBB GWAS that 
were in LD with the previously reported variant and 124 were genome-wide significant in the EAWAS. 
We confirmed 332 known loci at P≤5x10-5 and 344 (95%) were nominally significant (P≤0.05). 
 
Comparison of conditional analyses in the EAWAS and UKBB GWAS 
 
For eight of the known regions in Table 2 the common BP-associated SNVs were not available on 
Exome array, but independently associated rare/low-frequency variants had been identified. We 
therefore verified that these associations were valid using the dense genomic coverage in UKBB. At 
NOX4, ZFAT, GEM, MYO1C and LTBP4 the same variants (or proxies r2>0.9) were identified with 
FINEMAP in UKBB (Table 3) as with GCTA for the EAWAS (Table 2). At GEM and NOX4 two rare 
BP-associated SNVs were identified in both genes in addition to the previously reported common 
variant associations (Table 3; Supplementary Table 8).  At FBXL19, a rare missense variant was 
independent of the common variant signal in the EAWAS, (Table 2, Supplementary Table 8) while in 
the FINEMAP analyses in UKBB, an intron variant in STX4 was in LD (r2=0.88) with the FBXL19 
missense variant. (A second rare SNV, rs2234710, upstream of BCL7C, was independent of the STX4 
and common variant associations at this locus, in UKBB.) At FOXS1, a rare missense variant was 
identified as the top association in the EAWAS, while in the FINEMAP UKBB analyses an intronic 
variant in MYLK2, which is in LD (r2=1 in 1000 genomes EUR) with the FOXS1 variant was identified, 
and although the FOXS1 SNV is a more attractive candidate causal variant as it is missense, MYLK2 
is an attractive candidate gene as it is targeted by the drug Fostamatinib, which is used for the treatment 
of chronic immune thrombocytopenia and hypertension is reported as a side effect of Fostamatinib. 
Therefore it is likely that the rare/low-frequency associations at these loci are valid and independent 
of the established common variant associations. 
 
Annotation of BP-associated variants 
 
We used extensive bioinformatic approaches to collate functional annotations of variants and genes 
within the novel and known BP-associated loci. For variants, we used VEP3 to obtain comprehensive 
functional characterization of sentinel and conditionally independent variants and their proxies (r20.8; 
using the same approach as for locus definitions) including gene location, conservation and amino acid 
substitution. 
 
Across all 589 BP loci considered, 45% of the independent BP-associated rare variants were coding, 
while amongst the common variants, 20% were coding, in part reflecting the exome-centric design of 
the EAWAS. Twenty-one rare and 43 low-frequency variants were within regulatory elements 
including enhancers, promoters, CTCF binding sites, transcription factor binding sites and open 
chromatin regions highlighting genetic control of BP levels through gene expression. 
 
Gene-based association tests sensitivity analyses 
 
Amongst the genes that map to our newly identified BP-associated loci, ten from the EAWAS 
(SCMH1, FILIP1L, CEP97, G6PC2, PHC3, HAUS6, PLCB3, TBX5, SOS2, NEK9) and four from the 
RV-GWAS (NEK7, PHC3, TBX5, GATA5) were associated with BP (P<2.5x10-6). Analyses 
conditional on the top SNV in the gene showed that the associations were attributable to a single rare 
variant identified in the single variant analyses and not likely to be due to multiple rare SNVs 
(Supplementary Table 9). 
 
We tested the genes that mapped to the 362 previously reported BP loci. In the EAWAS, 21 genes 
within known loci, were associated with BP (P<2.5x10-6; Supplementary Table 9) and ten genes (two 
not in the EAWAS list, ZNF646 and COL17A1) were associated in the RV-GWAS (P<2.5x10-6; 
Supplementary Table 9). Analyses conditional on the top SNV in the gene, showed that six of these 
gene associations were due to multiple rare SNV associations (GEM, NPR1, DBH, COL21A1, NOX4 
and AGT: SKAT conditional P<1x10-4; Supplementary Table 9). To test whether the associations were 
due to LD with known common BP-associated variants, we also performed SKAT tests conditional on 
the known common variants in the individual loci. Five of the genes, NPR1, DBH, COL21A1, NOX4, 
GEM, were associated with BP independently of both the common variant associations and the top 
SNV in the gene (P≤1x10-5; Supplementary Table 9) confirming the findings in the single variant 
conditional analyses (Supplementary Table 8).  
 
To assess sensitivity to the MAF threshold, we repeated the gene-based tests using a MAF<0.05 
threshold. No genes with multiple rare/low-frequency SNVs were identified outside of known or novel 
regions (conditional SKAT P>0.0001; Supplementary Table 9). Of the 27 genes that were associated 
in the novel loci (P<2.5x10-6), the association at PLCB3 with DBP was due to multiple DBP-associated 
SNVs (P=2.63x10-6; Supplementary Table 9) consistent with the conditional single variant analyses 
that identified one rare and one low-frequency variant associated in this gene (Supplementary Table 
8). Of the 67 genes associated in known regions, nine (NPR1, DBH, COL21A1, NOX4, CEP120, 
LARP4, PLCE1, NOS3 and TBC1D32) were due to multiple SNVs, and the associations with NPR1, 
COL21A1, and CEP120 were not due to common variant associations (conditional SKAT P<1x10-5; 
Supplementary Table 9, 10). In total, seven genes, one in a novel region (PLCB3) and six in known 
regions (NPR1, DBH, COL21A1, NOX4, GEM and CEP120) were implicated in BP regulation with 






Rare variant gene-set enrichment analyses 
 
Lists of genes representing various pathways and biological processes were constructed from the 
following sources: GO (download from http://geneontology.org/ on December 9, 2018, using the files 
go-basic.obo and goa_human.gaf), GTEX (download from https://gtexportal.org on December 9, 
2018, using the file GTEx_Analysis_2016-01-15_v7_RNASeQCv1.1.8_gene_median_tpm.gct.gz), 
KEGG (downloaded from ftp.pathways.jp on December 9, 2018 using the files hsa.list and 
map_title.tab), MGI (downloaded from http://www.informatics.jax.org downloads/reports on 
December 9, 2018, using the files MPheno_OBO.ontology.obo, HMD_HumanPhenotype.rpt and 
MGI_PhenoGenoMP.rpt) and Orphanet (downloaded from http://www.orphadata.org/data/ORDO/ on 
December 9, 2018, using the files ordo.owl).  For GTEx, a gene set for a tissue was defined as the set 
of all genes with highest expression in that tissue.  In the cases of the ontologies (GO, MGI, Orpha) 
gene sets were constructed by first collecting the genes annotated to each specific node and then rolling 
these annotations up to each parent node recursively to the top of the ontology.  For the MGI data the 
mouse to human orthology mappings provided in the source files were used.  All gene references were 
mapped to entrez IDs using Homo_sapiens.gene_info file obtained from 
ftp://ftp.ncbi.nih.gov/gene/DATA/GENE_INFO/Mammalia.  Genes not listed as “protein-coding” 
genes in entrez genes were omitted, as were genes with no chromosomal mappings in the hg38 
reference genome assembly.  Gene sets with only a single gene were eliminated from further 
consideration. 
We tested whether genes near rare BP-associated SNVs were enriched in gene sets from Gene 
Ontology (GO), KEGG, Mouse Genome Informatics (MGI) and Orphanet (Methods; Supplementary 
Table 4). These (rare variant) genes from both known and novel loci were enriched in BP-related 
pathways (Bonferroni adjusted P<0.05, Methods; Supplementary Table 13) including “regulation of 
blood vessel size” (GO) and “renin secretion” (KEGG). Genes implicated by rare SNVs at known loci 
were enriched in “tissue remodeling” (GO) and “artery aorta” (GO). Genes implicated by rare SNVs 
at new BP-loci were enriched in rare circulatory system diseases (that include hypertension and rare 
renal diseases) in Orphanet. 
 
Drug target prioritisation 
The list of genes nearby the low-frequency and rare variant associations in both novel and previously 
identified loci (Supplementary Table 12) were cross-referenced in the list of “druggable” genes from 
Finnan et al.4. Those that were potentially targetable were queried in Open Targets (opentargets.org) 
and drugbank (www.drugbank.ca/) to assess whether there were pre-existing molecules for these 
genes.  
Information on some new BP genes 
 
Below is provided some information on some interesting genes harbouring or neighbouring new BP-
associated rare/low-frequency variants. 
 
ZFHX3 
The low frequency missense variant rs62051555 (p.Gln2014His), located in exon eight of the 
transcription factor, zinc finger homeobox 3 (ZFHX3), is associated with increased levels of SBP and 
PP. Interestingly, ZFHX3 plays a role in the left-right patterning of cardiac atria during development, 
with changed expression of genes important for sidedness 5. Mice with cardiac-restricted knockdown 
of ZFHX3 have cardiomyopathy, impaired left ventricular function, atrial enlargement, altered atrial 
electrophysiology properties (increased conduction velocity) 5 and abnormalities in calcium 
homeostasis 6,5. They also have severely dilated and fibrosed atria with a large mass consistent with 
thrombus and a significantly shorter life span compared to control animals 5. The above abnormalities 
can increase susceptibility to atrial fibrillation (AF) 5. ZFHX3 has been reported multiple times to be 
associated with AF 7,8,9,10,11,12, a major risk factor for cardioembolic stroke13 14,15.  The association 
between AF and an increased risk for cardiovascular morbidity and mortality cannot be explained by 
thromboembolism alone, and patients with AF have increased beat-to-beat BP variability, which may 
adversely affect vascular structure and function 16, which can potentially influence BP.   
 
LAMA5 
Two low-frequency missense variants, rs11699758 (p.Val1757Ile) and rs13039398 (p.Arg1667Trp), 
residing in LAMA5, are associated with decreased SBP and PP. LAMA5 encodes an extracellular matrix 
laminin α5 chain. Laminins are a group of α/β/γ glycoprotein heterotrimers, which constitute the main 
noncollagenous component of basement membranes 17. Laminin α5 plays an important role in 
embryogenesis, and Lama5-/- mice embryos do not survive until birth 17. Particularly, laminin 
heterotrimers containing laminin α5 chain are involved in glomerulogenesis, and are essential for the 
formation of the glomerular basement membrane, so that Lama5-/- embryos have failed 
vascularization of glomeruli in kidneys and even present with kidney agenesis 18. 
Moreover, endothelial cell basement membrane laminin α5 is required for a normal shear response by 
resistance arteries 19. The loss of laminin α5 from endothelial basement membranes in Tek-
Cre::Lama5-/- mice results in an almost complete elimination of dilation in response to increased shear 
stress, which correlates with decreased endothelial cell cortical stiffness, decreased size of integrin 
beta1-positive/vinculin-positive focal adhesions and decreased junctional association of actin–myosin 
II 19. In vitro experiments suggest that arterial endothelial cells directly bind to laminin α5/β1/γ1 via 
β1 integrins and that this binding increases VE-cadherin stabilization at cell-cell junctions, required 
for an adequate shear response 19.  




The missense variant of HSPA4 (rs61755724, p.Ala159Thr) is associated with increase in DBP. Heat 
shock protein HSPA4 is a member of the HSP110 family and acts as a nucleotide exchange factor of 
HSP70 chaperones 20. Upregulated expression of Hspa4 is observed in murine hearts exposed to 
pressure overload and in failing human hearts 20. Furthermore, Hspa4-/- mice developed cardiac 
concentric hypertrophy and fibrosis with elevated expression levels of hypertrophic markers and an 
accumulation of polyubiquitinated proteins in neonatal hearts, suggesting that Hspa4-/- plays a role in 
protein quality control 20. 
 
MCL1 
The missense variant rs11580946 (p.Ala227Val), belonging to apoptosis regulator MCL1, is 
associated with decreased levels of SBP and PP. MCL1 participates in survival of haematopoietic stem 
cells 21, progenitor cells, effector lymphocytes and cardiomyocytes 22. Given its role in cell survival, 
MCL1 is a drug target for cancer-related phenotypes, with the small molecule inhibitor (antagonist) 
currently in 1 phase II trials and also for emergency treatment of acute angle-closure glaucoma and 
other conditions in which rapid reduction in intraocular pressure and vitreous volume is indicated 
(Supplementary Table 14). Cardiac-specific ablation of Mcl-1 in mice results in a rapidly fatal dilated 
cardiomyopathy, preceded by loss of myofibrils and cardiac contractility, abnormal mitochondria 
ultrastructure, defective mitochondrial respiration, and impaired autophagy 23.  
 
TBX5 
The newly identified rare variant rs77357563 (p.Asp111Tyr; predicted deleterious by SIFT) in TBX5, 
is adjacent to the known TBX3 region24-26 and highlights TBX5 as an additional candidate gene. TBX5 
is essential for normal cardiac development. Mutations in TBX5 are known to cause various congenital 




We observed rare variants in both intergenic and intronic regions, one rare intergenic variant 
rs12135454 is located near TGFB2. Prior work has indicated the TGFβ pathway as important in the 
genetics of BP traits29. Mutations in TGFB2 cause Loeys-Dietz syndrome 4, a condition which includes 




Mendelian Randomisation to assess the effect of metabolites on BP 
 
We tested for pleiotropic effects of the IVs used for the 3-methylglutarylcarnitine(2) using two models. 
Firstly, we included any of the 14 metabolites in the analyses that shared at least one IV with 3-
methylglutarylcarnitine(2) in a multi-variable MR model (three metabolites in total). Secondly, we 
included glycine in a multi-variable MR model with 3-methylglutarylcarnitine(2) as these two 
metabolites shared several IVs but glycine was not in our list of 14 metabolites analysed and we have 
recently shown that glycine is causal for BP31. 3-methylglutarylcarnitine(2) was consistently and 
significantly associated with DBP (P < 0.05) in the multi-variable MR models. Notably, we found that 
3-methylglutarylcarnitine(2) was independently associated with DBP adjusting for the effect of 
glycine. Sensitivity analysis from multi-variable MR-Egger showed little evidence that the Egger 
intercept was deviated from zero for both models (Pintercept > 0.01).       
 
We found genetically determined 3-methylglutarycarnitine (2) was predictive of DBP in both 
univariable and multivariable MR analyses (Supplementary Table 16).  3-methylglutarylcarnitine 
belongs to the class of organic compounds known as acyl carnitines involved in long-chain fatty acid 
metabolism in mitochondria and in leucine metabolism. It is a diagnostic metabolite of 3-hydroxy-3-
methylglutaryl-coenzyme A lyase deficiency, an inborn error of metabolism in which the body cannot 
process leucine or generate ketones32, with dilated cardiomyopathy as a complication33. Leucine has 
been shown to increase hypothalamic mTORC1 leading to an increase in BP34. A prospective clinical 
study also found that 3-methylglutarycarnitine was significantly lower in maternal first-trimester 
serum of fetal congenital heart defects (CHDs) than healthy controls35. 
 
Kidney expression data 
 
Datasets, expression and SNP genotyping 
The cis-eQTL meta-analysis was carried out using data from two projects: TRANScriptome of renaL 
humAn TissuE (TRANSLATE) Study (N=186) and The Cancer Genome Atlas (TCGA) study (N=99).  
The same quality control filters, data processing and analyses methods were applied to both datasets. 
Gene expression was quantified in terms of transcripts per million (TPM) using Kallisto36. Outlier 
samples were removed based on a statistic described in Wright et al. 37 or based on pairwise correlation 
between samples, where samples with median correlation <0.8 were excluded as per ‘t Hoen et al. 38. 
Only genes on autosomal chromosomes were selected for the analysis. Gene expression threshold was 
set at TPM>0.1 in at least 20% of samples within each study/sequencing batch and read counts ≥ 6. A 
gene was also removed if its interquartile range was zero. Only genes that passed all of the above 
RNA-seq quality control filters in both studies were used in the analysis.  
Gene-level TPM values were normalised as follows. First, log2 of TPM values were normalised across 
samples using robust quantile normalisation. Second, the normalised gene expression values were 
transformed using rank-based inverse normal transformation. Third, to account for hidden variation in 
RNA-seq data due to technical processing (such as batch effects or sample processing in pre-
sequencing stage), we used probabilistic estimation of expression residuals (PEER) method39 and 
estimated 30 hidden factors for TRANSLATE Study and 15 for TCGA. The numbers of hidden factors 
were chosen based on sample sizes of each dataset as recommended in GTEx eQTL analyses40,41.  
In TRANSLATE Study, genotyping was done using Infinium HumanCoreExome-24 BeadChip arrays 
and the allele calls were made using Genome Studio. In TCGA, genotyping was done using Affymetrix 
Genome-Wide Human SNP Array 6.0 and the allele calls were made using Birdseed. The following 
quality control filters were applied to genotype data. Samples were excluded if their genotyping rate 
was <95%, their heterozygosity rate was outside ± 3 standard deviations from the mean, they had 
cryptic relatedness with other individuals, were of non-white European genetic ancestry or had 
discordant sex information (inconsistency between declared and genotyped sex). Genetic variants were 
excluded if their genotyping rate was <95%, they mapped to Y chromosome or mitochondrial DNA, 
they had ambiguous chromosomal location, they violated Hardy-Weinberg equilibrium (HWE) 
(P<0.001) or if their minor allele frequency (MAF) was <5%.  
 
Genotype imputation was conducted using minimac342 with Haplotype Reference Consortium data as 
the reference panel. The imputation was performed on Michigan Imputation Server42. Post-imputation, 
we excluded duplicate variants, non-SNPs, variants with low imputation coefficient (R2<0.4), low 
frequency variants (MAF<5%) and variants that violated HWE (P<10-6). 
 
Multiple linear regression was used to test association between gene expression and genotype and the 
estimated coefficients from both studies were meta-analysed using inverse-variance weighted fixed 
effects. For each gene, only those SNVs within 1Mb of the transcription start/stop sites (cis) were 
included in the analysis. Two thousand permutations were used to derive the empirical distribution of 
the smallest P-value for each gene, which then was used to adjust the observed smallest P-value for 
the gene. The correction for testing multiple genes was based on false discovery rate (FDR) applied to 
permutation-adjusted P-values (via Storey’s method as implemented in the R package q-value) with a 
cut-off of 0.05. Furthermore, the thresholds for nominal P-values were derived using a global 
permutation-adjusted P-value closest to FDR of 0.05 and the empirical distributions determined using 
permutations.  
The BP SNVs (N=358 at 214 loci, see Supplementary Table 1b) were considered or proxies (r2>0.8) 
if the sentinel SNV was not available. For reporting we only considered genes with FDR<0.05 and 
significant cis-eQTLs at P<5×10−8. If the BP-associated SNV and the eQTL were the same or in high 
LD (r2>0.8), the BP SNV was reported as an eQTL 
 
cis-eQTL meta-analysis 
The association between gene expression and genotype was conducted using multiple linear regression 
with normalised gene expression as the dependent variable and genotype dosage, sex, top three 
genotype-derived principal components and the estimated hidden factors (30 for TRANSLATE Study 
and 15 for TCGA) as independent variables. The estimated coefficients from both studies were 
combined using inverse variance method. Only SNPs within 1Mb from the closest bound of a gene 
were considered. The correction for multiple testing for analysis of each gene with its in-cis SNPs was 
conducted using the permutation test, where the distribution of the smallest meta-combined P-value 
was determined using 2,000 permutations. At each permutation, the genotype sample labels were 
permuted but kept coupled with the sample labels of the top three genotype principal components for 
TRANSLATE Study data and TCGA data, separately. For each gene, the associations between its 
expression and its in-cis SNPs were re-estimated and the smallest meta-combined P-value recorded. 
Finally, for each gene the SNP with the smallest meta-combined P-value was identified and adjusted 
using the corresponding empirical distribution of the smallest meta-combined P-values for that gene.  
False discovery rate was determined using q-values from the qvalue R package. The permutation 
corrected P-values were used for calculating the false discovery rate (FDR) with a cut-off of 5%.  
A threshold for nominal meta-combined P-values for SNPs that did not have the smallest meta-
combined P-values was calculated as follows. First, a global permutation-adjusted P-value, pt, was 
chosen to be the permutation-adjusted P-value for the gene with FDR closets to 5%. Then for each 
gene, a threshold for meta-combined nominal P-values was chosen to be the probability of observing 
a value less than or equal to pt using the gene's empirical distribution of the smallest meta-combined 
P-values. 
In total, 16,333 genes with at least one in-cis SNP and 4,862,143 SNPs with at least one in-cis gene 
were used in the analysis, resulting in 60,984,484 models. After correction for multiple testing, 4,431 
genes passed FDR 5% cut-off. There were 425,096 statistically significant gene-SNP pairs that passed 
nominal P-value cut-offs: 317,425 unique SNPs associated with 4,431 genes.  
 
The BP SNVs (N= 358 at 214 loci, see Supplementary Table 1b) were considered or proxies (r2>0.8) 
if the sentinel SNV was not available. For reporting we only considered genes passing the 5% FDR 
cut-off and significant cis-eQTL signal(s) at P < 5 × 10−8. We reviewed the results for the most strongly 
associated cis-eQTL for the corresponding transcript.  If the BP SNV and the eQTL were the same or 
in high LD (r2>0.7), the BP SNV was reported as an eQTL. The results are summarized in 
Supplementary Table 18.  
 
Colocalisation of BP associations and eQTL 
 
Colocalisation analyses using the common variant results identified 32 unique BP-associated loci 
where the new BP-associated variant colocalised with the eQTL for 54 unique genes in GTEx tissues 
highlighting potential candidate genes. Many of the novel BP variants in genes including those in 
PHACTR1, TIE1, CTSK, LTBP1, CRIM1, TIPARP that colocalised with gene expression in GTEx in 
specific cardiovascular tissues, are also associated with CVD related phenotypes43-56. TIE1 is involved 
in angiopoietin function in vascular remodelling and inflammation57. In the mouse, mutations in Tie1 
cause many cardiovascular phenotypes including small heart development, abnormal vascular 
endothelial cell morphology, abnormal endocardium morphology and abnormal heart atrium 
morphology47,58. Together these observations make TIE1 a plausible candidate gene. Crim1 
KST264/KST264 mice implicate Crim1 in the regulation of vascular endothelial growth factor-A 
activity during glomerular vascular development55. Tiparp negative mice have kidney defects, 
including defects in smooth muscle cell number and location59. 
 
Tissue and cell enrichment analyses using DEPICT 
 
We used DEPICT (Data-driven Expression Prioritized Integration for Complex Traits) as a 
complementary enrichment analysis to (1) identify tissues and cells in which genes at novel and 
previously reported BP loci are highly expressed and  2) to test for enrichment in gene sets associated 
with biological annotations, which included molecular pathways and phenotype data from mouse 
knockout studies. Two analyses were performed one involved all BP variants reported previously for 
BP traits (that were genome-wide significant in our dataset; Supplementary Table 5, 8) and a second 
set including all previously reported BP variants and variants at new loci, i.e. newly validated genome-
wide significant SNVs (including the rare variants identified in the RV-GWAS) and any independent 
variants at these loci (Supplementary Tables 2, 3, 7).  We report significant enrichments with a false 
discovery rate of 1%. We found the most significant enrichments were observed for the urogenital 
system (P=1.25x10-16), cardiovascular system (P=2.01x10-13) and endocrine system (P=1.78x10-11) 
(Supplementary Table 13). 
 
Enrichment of BP-associated SNVs in DNase I-hypersensitive sites 
 
To investigate cell-type-specific enrichment within DNase I-hypersensitive sites we used FORGE, 
which tests for enrichment of SNVs within DNase I-hypersensitive sites in 299 cell types from the 
Epigenomics Roadmap Project and 125 cell lines from ENCODE60. All common and rare non-coding 
novel and conditionally independent validated variants from EAWAS, and SNVs from the RV-GWAS 
(all P<5.0x10-8) were included (Supplementary Tables 2, 3, 7). BP-trait specific analyses were not 
performed. We supplemented this listing to include all novel rare, low frequency and common variants 
from FINEMAP (variants not in LD (r2>0.6) with a previously reported BP SNV (851 variants; 
Supplementary Table 8). In total 1,055 variants were included in the input from which 37 that were 
not in 1000 genomes Phase I and 64 that were in LD (r2>0.8) with the data were excluded leaving 954 
for analysis. Enrichment was calculated by taking the Bonferroni corrected P-values from a binomial 
test comparing overlap of the supplied SNPs with 100 background SNP sets. 
 
Significant results (Bonferroni corrected P-value<0.01) were observed across 15 tissues 
(Supplementary Table 13) in the ENCODE dataset. The strongest enrichments were in blood vessels, 
heart, skin, connective tissue, lung and epithelium (Z-score >6). These enriched tissues are similar to 
those reported for common BP associated SNVs29. Testing for enrichment in the Epigenomics 
Roadmap project indicated striking enrichment of BP SNVs in fetal kidney and fetal lung tissues (renal 
pelvis, renal cortex, renal kidney and lung, Z score=300) and significant enrichment across a further 
12 tissues (new Supplementary Table 13).  
 
Phenome-wide associations of the new common SNV BP loci  
 
To identify diseases and other intermediate phenotypes associated with the novel BP variants 
(Supplementary Tables 2, 3), we performed a lookup of sentinel and conditionally independent variants 
and their proxies (r2≥0.8) against publicly available GWAS data using PhenoScanner61. A list of 
datasets queried is available on the Phenoscanner website. Results were filtered to include association 
with P<5x10−8 for common variants and P<1x10-4 for rare variants. Either the sentinel variant or the 
proxy with the smallest P-value for each trait was further investigated.  
We also queried PhenoScanner for associations with publicly available eQTL and pQTL. 
 
Two BP-associated loci were in high LD (r2>0.8) with alcohol consumption variants. Variants at four 
new BP loci were in high LD with red blood cell trait associated SNVs, in particular haemoglobin, and 
one of these was also shared with iron traits (Figure 3). One locus was in LD with platelet traits and 
one with a plasminogen related trait. The new BP variants were also in high LD with variants 
associated with eye diseases for which hypertension is a risk factor: two with age-related macular 
degeneration and two with exfoliation glaucoma. The BP associated variant in CASC16 was shared 
with Parkinson’s disease. Telomere length has also been linked to aging and a variant at the MYNN 
locus was in LD with a telomere length associated variant.   
 
Colocalization of BP-associated SNVs with cardiometabolic traits in the EAWAS 
 
To estimate the probability that BP shared the same causal variant with other CVD risk factors, we 
conducted a co-localisation analysis. Using GWAS results from CVD risk factors (BMI62, HDL 
Cholesterol63, LDL Cholesterol63, Triglycerides63, fasting glucose64, type 2 diabetes65 and CAD66), we 
first identified SNV-CVD risk factor associations at each of the novel BP-associated loci. Within each 
locus, we conducted a Bayesian test for co-localisation using all shared SNVs using the coloc package 
in R.67 Assuming that 1 in 10,000 SNVs are likely to be causal for either test trait, we applied the 
default prior probabilities for a SNV being associated with trait one only (p1), trait two only (p2), and 
with both traits (p12), with p1 and p2 set to 0.0001 and p12 set to 0.00001. 
 
High blood pressure is one of several risk factors that act in concert increase risk for cardiovascular 
disease (CVD). To explore the genetic relations between blood pressure and other CVD risk factors 
(obesity, elevated blood total cholesterol, low density lipoprotein cholesterol [LDL], and triglyceride 
levels,  high density lipoprotein [HDL] cholesterol levels, and diabetes),  we conducted colocalization 
analyses using our  blood pressure genetic results in conjunction with summary GWAS of other risk 
factors (body mass index68, LDL cholesterol63, triglycerides63, HDL cholesterol63, fasting glucose64, 
type 2 diabetes65 and coronary artery disease (CAD)66) using the COLOC package67 in R to determine 
whether the same causal variant at each locus was associated with both blood pressure and CVD risk 
factor (Methods). At a posterior probability of both traits colocalising (H4) >90% (Supplementary 
Table 21), we found that blood pressure (DBP, SBP, PP) shared associated SNVs with CAD on 
chromosome 6 (SLC29A1/RP11-344J7.4 locus) , chromosome 19 (APOE/APOC1/GIPR/QPCTL), 
chromosome 20 (KCNB1/B4GALT5), chromosome 21(AP000318.2); with lipids (HDL cholesterol , 
LDL cholesterol and triglycerides) on chromosome 1(CD164L2), chromosome 3 (LINC02029), 
chromosome 4 (PPP3CA and PDGFC), chromosome 5 (C5orf67), chromosome 6 (SLC29A1 and 
LINC01625), chromosome 7 (KLF14), chromosome 12 (BCL7A), chromosome 19 (ZC3H4); with 
BMI on chromosome 1(ZZZ3), chromosome 2 (ACMSD),chromosome 4(PPP3CA), chromosome 5 
(RP11-6N13.1), chromosome 6 (FOXO3), chromosome 7(HIP1 and KLF14), chromosome 
16(CNOT1), chromosome 19 (ZC3H4); with fasting glucose on chromosome 2 
(SPC25/ABCB11/G6PC2), chromosome 11 (MTNR1B/SNRPGP16); and with type 2 diabetes on 
chromosome 3 (PPARG) (Supplementary Figure 4).  
 
Mendelian Randomisation (MR) analyses of CVDs  
 
We applied Mendelian randomisation (MR) to estimate the effects of blood pressure on CVD traits in 
a two-sample MR framework. The MR approach was based on the following assumption: (i) the 
genetic variants used as instrumental variables (IVs) are associated with blood pressure. (ii) the genetic 
variants are not associated with any confounders of the exposure-outcome relationship. (iii) the genetic 
variants are associated with the outcome only through change in BP i.e. a lack of pleiotropy. 
 
The inverse-variance weighted (IVW) method with a multiplicative random-effect model69, MR-Egger 
and MR-PRESSO were used. We also performed several sensitivity analyses to assess the robustness 
of our results to potential violations of the Mendelian Randomisation assumptions given these analyses 
have different assumptions for validity.  To assess instrument strength, we computed the F statistic70 
for the association of genetic variants with SBP, DBP and PP, respectively.  MR-Egger regression 
generates valid estimates even if not all the genetic instruments are valid, as long as the InSIDE 
(Instrument Strength Independent of Direct Effect) assumption holds71 and also test if there is 
unbalanced pleiotropy.  MR-PRESSO permits removal of outlier IVs72.  To minimise pleiotropy, we 
removed SNVs associated with cardiovascular traits, including cholesterol level 
(LDL/HDL/triglycerides), smoking, Type 2 diabetes (T2D) and Atrial Fibrillation (AF) 
(Supplementary Table 22c).  Although these methods may have different statistical power, the 
rationale is that if these methods give a similar conclusion regarding the association of BP and CVD, 
then we are more confident in inferring that the positive results are unlikely driven by violation of the 
MR assumptions73.   
 
We performed a genetic analysis of BP plus BP trait specific analyses of SBP, DBP, PP (online 
methods) using both previously published and newly identified BP SNVs.  We considered any stroke, 
any ischemic stroke, large artery stroke, cardioembolic stroke, small vessel stroke and coronary artery 
disease (CAD) (online methods).  As expected, blood pressure was positively associated with increased 
stroke (any stroke) risk (odds ratio (95% confidence interval) = 1.42 (1.36 - 1.49) per increase of one 
standard deviation in inverse-normal transformed of generic blood pressure (BPgeneric), P = 5.70  
10-50; 1.71 (1.61 - 1.82) per increase of one standard deviation of inverse-normal transformed of SBP, 
P = 1.35  10-67; 1.53 (1.44 - 1.64) per increase of one standard deviation in inverse-normal 
transformed of DBP, P = 2.34  10-37; 1.39 (1.31 - 1.47) per increase of one standard deviation of 
inverse-normal transformed of PP, P = 3.62  10-28).  MR-EGGER and MR-PRESSO gave similar 
results (Supplementary Table 22) and no significant pleiotropy was detected (P>0.01 for the MR-
EGGER intercept; Supplementary Table 22). The positive association with stroke subtypes were 
statistically significant (P<0.00069; Figure 4, Supplementary Table 22), with the largest effect size of 
blood pressure on large artery stroke while smallest effect was with cardioembolic stroke.  SBP was 
the primary association - with the largest effect size, with any of the CVD traits investigated (Figure 
4, Supplementary Table 22), suggesting that SBP is the most sensitive BP measure, consistent with 
clinical practice.  
 
In MR-Egger, we tested if the intercept estimate deviated from zero for the inference of genetic 
pleiotropy, i.e. where certain genetic variants affect the outcome through a different biological pathway 
from BP.  In practice, there was little evidence that the MR-Egger intercept deviated from zero for any 
BP traits and any CVD traits, e.g. SBP and large artery stroke (intercept = 0.0026, SE = 0.0025, P = 
0.31).     
 
With MR-PRESSO, we used the outlier test embedded in the R package ‘MR-PRESSO’ to remove 
outlier due to pleiotropy and estimated the causal effects by IVW method before and after outlier 
removal.   The causal effects (OR) after outlier-corrected were similar to the ‘raw’ estimates 
(Supplementary Table 22: with MR-PRESSO results), indicating that there was little evidence for 
genetic pleiotropy.   
 
To quantify the strength of the selected instrumental variants for each “exposure (BP) – outcome 
(CVD)” pairs, we computed F-statistics (Supplementary Table 22).  The F-statistics for the 964 SNVs 
for the “BP generic – Any Stroke” ranged from 11 to 767 with a median of 44, well above the threshold 
of F > 10 typically recommended for MR analysis 74. 
 
When performing a multi-variable MR analyses including both SBP and DBP in the model for the 
inference of their effects on stroke, we found that the effect of SBP is still significant after adjusting 
for DBP, but not vice versa.   Interestingly, we found that the effect of SBP on large artery stroke 
(P=7.21  10-23; OR(95%CI)=2.62 (2.16, 3.17)per increase of one standard deviation of inverse-
normal transformed of SBP) after adjusting for DBP is larger than the univariate MR estimation 
(P=1.30  10-33; 2.19 (1.93, 2.48)), while the effect of DBP becomes negatively associated with stroke 
risk (P=6.28  10-2; 0.832 (0.686, 1.01)) adjusting for SBP (although this did not pass our P-value 
threshold for significance).  This is consistent with the findings from the univariable MR analysis of 
PP on stroke risk, which showed that PP has the largest effect on large artery stroke. 
 
We also performed sensitivity analysis using multivariable MR-Egger to correct for pleiotropy75.  
Similar to the univariable MR-Egger results, there was little evidence that the multi-variable MR-




Variance explained by BP-associated SNVs 
 
We used 5,390 individuals from the Danish cohort within EPIC-CVD76 to calculate variance explained 
as these participants were not used as part of the discovery set, genotyped using the Illumina Human 
CoreExome BeadChip array. SBP and DBP were measured twice at baseline and the average was used. 
Using a genetic risk score to represent all the known and new BP associations, we fitted a linear 
regression of each transformed BP trait against age, age2, sex, BMI, top 10 genetic principle 
components, and CVD event (defined as any first CVD event) as a factor to obtained the variance 
explained by covariates (R2covariants).  We then fit a second linear model for the transformed BP trait 
with all covariates plus a GRS to obtain the variance explained by all variables (R2all).  Thus, the 
variance explained by GRS of BP genetic variants was: 
R2GRS = R2all - R2covariants 
We considered five different levels of GRS for each BP trait: (i) all independent common variants 
(MAF >= 0.01); (ii) all independent rare variants (MAF < 0.01); (iii) all independent SNVs within 
known loci; (iv) all independent SNVs within novel loci; (v) all independent SNVs. 
 
The estimated percentage of variance in BP explained by all the BP-associated SNVs (known and 
novel) was: 4.54 for SBP, 3.54 for DBP, and 5.39 for PP (Supplementary Table 26).  This is consistent 
with previous reports. Within the novel loci, ~0.6% of the variance is explained by the new 
independent SNVs, with <0.2% of the variance explained by independent rare variants (although we 
note only ~ 50% of rare variants were available for this calculation).  
 
Supplementary Table 26: 
Percentage of variance explained for BP traits in the EPIC-CVD Danish cohort.  
BP trait 
Number of SNPs for constructing the GRS      
ALL COMM RARE KNOWN NOVEL      
SBP 778 734 44 507 271      
DBP 742 708 34 494 248      
PP 802 760 42 569 233      
           
BP trait 
% variance explained by GRS      
ALL COMM RARE KNOWN NOVEL      
SBP 4.54 4.55 0.17 4.54 0.62      
DBP 3.541 3.421 0.183 3.311 0.601      
PP 5.39 5.4 0.05 5.09 0.59      
ALL = GRS of all associated variants for any BP trait      
COMM = GRS of all common and low-frequency variants (MAF >= 
0.01)       
RARE = GRS of all rare variants (MAF < 0.01)       
KNOWN = GRS of all known variants        
NOVEL = GRS of novel variants identified in current study      
  
UK Biobank specific analyses 
 
The UK Biobank (UKBB) is a large prospective study of 502,642 participants aged 40–69 years when 
recruited between 2006–2010 at 22 assessment centres across the United Kingdom77,78. The study has 
collected and continues to collect a large amount of phenotypic measurements including systolic and 
diastolic blood pressure (BP). 
 
Processing, quality control and analyses of the data provided by UK Biobank, were performed at two 
sites independently and were confirmed to be concordant at each step of the process. 
 
Blood pressure measurement  
BP was measured twice in a seated position after two minutes rest with a one minute rest before the 
second measurement [UK Biobank. UKB : Resource 100225 - Blood-pressure measurement 
procedures using ACE - Version 1.0. Available at: 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=100225. Accessed October 2, 2017]. An appropriate 
cuff and an Omron 705IT digital BP monitor, was used to measure BP in the majority of participants 
(UK Biobank data fields: SBP: f.4080.0.0 and f.4080.0.1; DBP: f.4079.0.0 and f.4079.0.1). If the 
largest cuff size was too small for the participant, or the electronic BP monitor failed, a 
sphygmomanometer with an inflatable cuff was used in conjunction with a stethoscope to perform a 
manual measurement (UK Biobank data fields: SBP: f.93.0.0 and f.93.0.1; DBP: f.93.0.0 and f.93.0.1). 
Of the 502,642 UKBB participants, 488,366 had both BP measurements and genotype data available, 
we therefore restricted phenotype quality control (QC) to these individuals. At baseline there were 
446,611 participants with two automated BP measurements; 14,133 participants with one automated 
and one manual measurement and 26,615 with both manual measurements. The 1,007 samples with 
only one blood pressure measurement at baseline were excluded. Comparison of the BP distributions 
obtained using automated and manual approaches were concordant and reassured us both approaches 
were accurate. Individuals missing SBP or DBP at baseline assessment were removed (n=1,834). The 
mean of both measurements at baseline for a given participant was calculated to create an overall 
measure for SBP, DBP and PP. Phenotype QC was performed in R version v3.3.  
 
Blood pressure measurement quality control  Participants were excluded from analysis if  
1. the difference between the first and second blood pressure measurement > 99.9th percentile 
(n=857); 
2. covariates were missing: Age (n=0), gender (n=0), BMI (n=3105) using respectively UK 
Biobank data fields: f.21003.0.0, f.31.0.0 and f.21001.0.0; 
3. they were pregnant at time of blood pressure measurement (n=131) UK Biobank data field: 
f.3140.0.0;  
4. BMI >99.9th or <0.01 percentile (n=970). 
In total 483,515 participants remained following quality control.  
 
Adjustment of BP measurement for treatment effect For all UKBB participants that were on anti-
hypertensive medication at time of blood pressure measurement (n=48,800) we added 15mmHg to the 
mean observed SBP, 10mmHg to the mean observed DBP and 5mmHg to the mean observed PP.  
 
Definition of hypertension UKBB participants were defined as having hypertension when at least one 
of the following criteria was met: 
1. Mean observed SBP ≥ 140 mmHg 
2. Mean observed DBP ≥ 90 mmHg 
3. History of hypertension: which was defined using the “non-cancer illnesses and associated first 
diagnosis timestamp” collected through the verbal interview (UK Biobank data field: 
f.20002.0.0) at baseline assessment for each UKBB participant. That is, where the following 
codes: “1065 hypertension”, “1072 essential hypertension” are present in data field 
f.20002.0.0. No ICD codes were used to define hypertension.  
4. Use of anti-hypertensive medication: at a baseline survey, we used responses to the 
“Medication for cholesterol, blood pressure or diabetes” question for males and responses to 
the “Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones” 
question for females, both collected through the touchscreen questionnaire and providing 
information on regular medication use (UK Biobank data fields: f.6177.0.0 and f.6153.0.0, 
respectively). If a participant selected “2 Blood pressure medication” we defined this 
participant as having a current status of taking anti-hypertensive medication (27,931 females, 
22,630 males).  
255,794 individuals were defined as hypertensive and 227,721 were non-hypertensive. 
 
Genotype quality control (Supplementary Figure 5) 
We used both the Affymetrix UK Biobank/BiLEVE array genotypes and the Human Reference 
Consortium imputed genotypes78. Genotype QC was performed using PLINK1.9 and R v3.3. 
 
Defining a European set of UK Biobank participants Approximately 22,000 UKBB participants had 
a self-reported ethnic background outside of Europe78. Deviation from Hardy Weinberg Equilibrium 
(HWE) is often an indicator of a poorly genotyped variant. However, due to the ethnic diversity of the 
UKBB cohort, deviations from HWE could also be due to violation of the assumptions of HWE e.g. 
large differences in allele frequency in an ethnically mixed cohort. We therefore sought to define a 
genetically European group of UKBB participants using principal component analyses (PCA) with 
FlashPCA279. High-quality autosomal variants were selected for PCA based on an overall call rate 
≥99%; minor allele frequency (MAF) >=0.05 and HWE P≥10-5. Regions of the genome known to 
exhibit long-range linkage disequilibrium (LD) were removed (chr6:25–33.5 Mb, chr8:8–12 Mb, 
chr17:40.4–42.4 Mb) to ensure the PCs were picking up ancestry and not LD. These variants were 
then LD pruned so no pair of variants within a 100 variant window had R2>0.2. A final round of LD 
pruning was performed in a 1000 variant window.  
 
Having generated 50 PCs, we adopted the method of Astle et al.80, to identify ancestral outliers to be 
remove. In brief, a ‘genetic distance’,  
, between individual i and a hypothetical median ‘‘white British’’ 
participant was calculated, where Em represents the eigenvalue corresponding to PC, m (i.e. the genetic 
variance explained by PCm), Pim represents the score of individual i on PCm, Cm represents the median 
score on PCm of participants with self-reported White ancestry (defined as “British”, “Irish”, “White” 
or “Any other White background”).  
We used a threshold of genetic distance > 0.2 to identify non-Europeans, which resulted in the 
exclusion of 23,511 non-European participants.  
 
Batch level variant and sample QC Genotype QC was performed with the above defined European 
subset of participants, separately for each of the 106 UKBB genotyping batches. The following 
thresholds were applied to remove variants: call rate ≤ mean (call rate) - [ 3 x SD (call rate)]; HWE P-
value < 1x10-12 (MAF<0.01) or HWE P-value < 1x10-6 (MAF≥0.01). Variants that failed either call 
rate or HWE within a batch were excluded from the corresponding batch prior to batch-level sample 
QC. Within batch, samples with call rate < mean (call rate) - [3 x SD (call rate)] or Heterozygosity > 
(mean +/- 3SD) were removed (n=11,944).  
 
Variant and sample QC across all batches Variants that failed QC in >48 batches (UKBB array) or > 
3 batches (UK BiLEVE array) were excluded (n=23,221 SNVs). We excluded samples who’s genetic 
sex and phenotypically defined sex (as provided by the UKBB) were discordant (n=136 samples).  
After variant and sample QC across all batches we performed a second PCA with FlashPCA279 using 
the same approach to select variants for PCA as described above. A genetic distance measure of 0.175 
calculated using 8PCs (as described above) was used to remove a further 3,015 individuals of non-
European ancestry.  
 
Definition of an unrelated set of UK Biobank participants For analyses of hypertension, we chose 
not to use a mixed effects model due to limitations with calculating a full kinship matrix. Therefore, 
using the fully QC’d data, we defined a subset of unrelated UKBB participants using the kinship 
information provided by UKBB that lists the kinship coefficient of pairs of individuals up to 3rd degree 
relatives. We calculated sample call rate to guide which participant within a pair of relatives to remove. 
All pairs that shared individual(s) were aggregated into families. From each of these families the 
sample with the highest call rate was retained. If individuals within the family had the same call rate 
we chose the one that occurred first in the file.  
 
Imputation The pre-imputation variant QC, phasing and imputation performed on the combined 
UKBB and UK BiLEVE data has been described in detail elsewhere78. The genetic data were imputed 
using the Haplotype Reference Consortium (HRC) panel. Additional variants were available in the 
interim release of imputed using 1000G/UK10K data in 150,000 UKBB participants but were not part 
of the HRC imputation panel. We extracted 30,315 variants that were readily available in the first 
release UKBB imputation dataset and were genotyped on the exome array but not either of the 
Affymetrix arrays used by UKBB. After QC of these variants and using an information score threshold 
>0.3, 157,666 variants were available for analysis in ~150,000 participants from the interim release.  
Variants for which both genotype and imputation data were available, we used the imputed variant if 
the genotyping call rate was <0.98 and the variant was imputed with an information score >0.7. We 
used the genotyped data for all variants that did not satisfy these criteria. All variants that passed QC 
and were available in either the genotyped or imputed data alone were also analysed. 
 
In total, 39,312,035 imputed variants with info>0.3 of which 31,835,351 were low frequency or rare 
were analysed in GWAS of UKBB (175,430 were Exome array variants of which 59,824 variants were 
genotyped and 115,606 variants were imputed). A further 784055 genotyped variants were analysed 
of which 405,033 were rare or low-frequency. Of these, up to 175,430 variants were analysed in 
EAWAS (Stage 1), and up to 29,454,346 additional variants – in RV-GWAS (Stage 1) 
 
Final dataset used for exome content analyses Following QC, 156,481 variants from the UK-Biobank 
full release (were analysed in 445,360 participants of European ancestry) and 18,947 variants from the 
interim release were analyzed in 364,510 European participants with SBP, DBP and PP measurements. 
Following QC and transformation, 157,666 Exome array variants (62,032 genotyped and 95,634 


































Analyses of SBP DBP and PP  
Each of the continuous traits (SBP, DBP and PP) were regressed on baseline age, baseline age squared, 
gender, BMI and genotyping array using the lm function in R. The residuals from these regression 
models were rank transformed and inverse normalised and the resulting transformed SBP, DBP and 
PP residuals were analysed using linear mixed models implemented in BOLT-LMM (Version: v2.3). 
The set of QCd variants used for the second PCA were also used for BOLT-LMM model building. 
In total, 784,045 directly genotyped and 39,312,035 imputed variants (175,430 were Exome array 
variants of which 59,824 variants were genotyped and 115,606 variants were imputed) were analysed 
for association with SBP, DBP and PP in up to 445,415 individuals of European ancestry from UKBB.  
 
Analyses of hypertension  
Genetic analysis of exome array variants was performed for hypertension as a binary outcome in 
364,510 unrelated individuals (192,235 hypertensive cases and 172,275 controls) of European ancestry 
using SNPTEST (Version: v2.5.4-beta3). Analyses were adjusted for baseline age, baseline age 
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Supplementary Figure 1. Forest plots for unique rare SNVs associated with one or more 
BP traits. 
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Presented are estimated transformed effect and 95% CI (Beta+1.96*SE).  
Supplementary Figure 2. Mendelian randomization analysis for blood pressure level and risk 
of cardiovascular diseases.  
 
a. SBP -> All Stroke DBP -> All Stroke PP -> All Stroke 
   
b. SBP -> Ischemic Stroke DBP -> Ischemic Stroke PP -> Ischemic Stroke 
   
c. SBP -> Large Artery Stroke DBP -> Large Artery Stroke PP -> Large Artery Stroke 
   
d. SBP -> Cardioembolic Stroke DBP -> Cardioembolic Stroke PP -> Cardioembolic Stroke 
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e. SBP -> Small Vessel Stroke DBP -> Small Vessel Stroke PP -> Small Vessel Stroke 
   
f. SBP -> Coronary Artery Disease DBP -> Coronary Artery Disease PP -> Coronary Artery Disease 
   
   
Associations between genetically determined blood pressure traits (SBP, DBP and PP) and risk of All 
Stroke (a), Ischemic Stroke (b), Large Artery Stroke (c), Cardioembolic Stroke (d), Small Vessel 
Stroke (e) and Coronary Artery Disease (f) based on four MR methods: IVW, MR-Egger, Simple 
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Supplementary Figure 3 (a) Comparison of the P-values for association of the novel BP SNVs from 
the random effects meta-analyses and the fixed effects meta-analyses as provided in Supplementary 
Table 2. -log10(P-values) are plotted. (b) Minor Allele Frequencies (MAF) of the novel BP-
associations from Stage 1 of the EAWAS and the data request studies (MVP+deCODE+GENOA) 





                   
 
 
For each included variant, N is up to 864,822 participants in EAWAS Stage 1, and up to 448,666 




Supplementary Figure 4. Co-localisation of the newly identified BP-associated loci with 
cardiometabolic traits using the UKBB GWAS data.  
 
 
The locus number is provided for the novel locus with the nearest gene(s) in parentheses. 
  
Supplementary Figure 5. Flowchart summarizing quality control procedures applied to genetic data 
in UKBB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
